Electra offers high-risk, high-upside biotech exposure: a $492 million pipeline EV, differentiated ipsoprubart data, and a potentially transformational sHLH launch pathway.
Overview
Electra Therapeutics is a pre-revenue, late-clinical biopharmaceutical company developing targeted SIRP antibodies that selectively deplete pathogenic immune cells rather than broadly suppressing host immunity. Its lead program, ipsoprubart, is in the Phase 2/3 SURPASS registrational trial for secondary HLH and has shown 100% eight-week overall survival and 100% overall response in 12 frontline malignancy-associated sHLH patients, compared with historical two-month survival near 50% under toxic legacy regimens. ELA822, a SIRPγ-specific antibody, is in Phase 1 development for activated T-cell-mediated autoimmune disease, while ipsoprubart is also being tested in T-cell and NK-cell malignancies. **The company has no commercial revenue and substantial losses**, including a $48.9 million net loss in 6M 2026, but the upsized IPO raised approximately $350.0 million and produced roughly $420 million of pro-forma cash, with management projecting runway into 2029. At a $14.50 share price, market capitalization is approximately $910.17 million and enterprise value approximately $492.15 million after net cash. The valuation offers substantial upside if SURPASS succeeds, with catalysts including ELA822 data in H1 2027, oncology data and SURPASS enrollment in H2 2027, potential 2028 approval, and a 2029 launch.